Literature DB >> 8251473

NMR structural studies of the tight complex between a trifluoromethyl ketone inhibitor and the 85-kDa human phospholipase A2.

L A Trimble1, I P Street, H Perrier, N M Tremblay, P K Weech, M A Bernstein.   

Abstract

Arachidonyl trifluoromethyl ketone (AACOCF3) is a slow- and tight-binding inhibitor of the human cytosolic phospholipase A2 (cPLA2) [Street et al. (1993) Biochemistry 32, 5935]. 19F and 13C NMR experiments have been carried out to elucidate the structure of the cPLA2.AACOCF3 complex. One mole of AACOCF3 per mole of enzyme is tightly bound in the active site while excess molar equivalents of the inhibitor associate loosely and nonspecifically with hydrophobic regions of the protein. Incubation of the cPLA2.AACOCF3 complex with a 10-fold molar excess of a structurally related inhibitor allows the slow dissociation of the enzyme-inhibitor complex to be followed with 19F NMR. These results establish that the bound inhibitor is in slow exchange with the free ligand and that inhibition of the cPLA2 by AACOCF3 is not due to irreversible modification of the protein. AACOCF3 labeled with 13C at the carbonyl position was used to determine the nature of the bound inhibitor species. A comparison of the 13C NMR chemical shift value obtained from labeled enzyme-inhibitor complex (delta c 101.0 ppm) with the chemical shift values obtained from model compounds suggests that the enzyme-bound inhibitor species is a charged hemiketal. These results are very similar to those obtained previously with alpha-chymotrypsin and a peptidyl trifluoromethyl ketone inhibitor [Liang, T.-C., & Abeles, R. H. (1987) Biochemistry 26, 7603] and, by analogy with the serine proteases, a structural model for the cPLA2.AACOCF3 complex is proposed.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8251473     DOI: 10.1021/bi00210a002

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  19 in total

Review 1.  Role of cytosolic calcium-dependent phospholipase A2 in Alzheimer's disease pathogenesis.

Authors:  M T Gentile; M G Reccia; P P Sorrentino; E Vitale; G Sorrentino; A A Puca; L Colucci-D'Amato
Journal:  Mol Neurobiol       Date:  2012-05-31       Impact factor: 5.590

Review 2.  Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention.

Authors:  Edward A Dennis; Jian Cao; Yuan-Hao Hsu; Victoria Magrioti; George Kokotos
Journal:  Chem Rev       Date:  2011-09-12       Impact factor: 60.622

3.  Cytosolic phospholipase A2 as a molecular target for the radiosensitization of ovarian cancer.

Authors:  Rachael R Schulte; Amanda G Linkous; Dennis E Hallahan; Eugenia M Yazlovitskaya
Journal:  Cancer Lett       Date:  2011-05-28       Impact factor: 8.679

4.  Chemical screen reveals small molecules suppressing fragile X premutation rCGG repeat-mediated neurodegeneration in Drosophila.

Authors:  Abrar Qurashi; Huijie Liu; Laurie Ray; David L Nelson; Ranhui Duan; Peng Jin
Journal:  Hum Mol Genet       Date:  2012-02-01       Impact factor: 6.150

5.  Effects of pyrrophenone, an inhibitor of group IVA phospholipase A2, on eicosanoid and PAF biosynthesis in human neutrophils.

Authors:  N Flamand; S Picard; L Lemieux; M Pouliot; S G Bourgoin; P Borgeat
Journal:  Br J Pharmacol       Date:  2006-09-11       Impact factor: 8.739

6.  Synthesis of polyfluoro ketones for selective inhibition of human phospholipase A2 enzymes.

Authors:  Constantinos Baskakis; Victoria Magrioti; Naomi Cotton; Daren Stephens; Violetta Constantinou-Kokotou; Edward A Dennis; George Kokotos
Journal:  J Med Chem       Date:  2008-12-25       Impact factor: 7.446

7.  Mechanism-based inhibition of iPLA2β demonstrates a highly reactive cysteine residue (C651) that interacts with the active site: mass spectrometric elucidation of the mechanisms underlying inhibition.

Authors:  Christopher M Jenkins; Jingyue Yang; Richard W Gross
Journal:  Biochemistry       Date:  2013-06-10       Impact factor: 3.162

8.  Location of inhibitors bound to group IVA phospholipase A2 determined by molecular dynamics and deuterium exchange mass spectrometry.

Authors:  John E Burke; Arneh Babakhani; Alemayehu A Gorfe; George Kokotos; Sheng Li; Virgil L Woods; J Andrew McCammon; Edward A Dennis
Journal:  J Am Chem Soc       Date:  2009-06-17       Impact factor: 15.419

Review 9.  Calcium-independent phospholipases in the heart: mediators of cellular signaling, bioenergetics, and ischemia-induced electrophysiologic dysfunction.

Authors:  Ari Cedars; Christopher M Jenkins; David J Mancuso; Richard W Gross
Journal:  J Cardiovasc Pharmacol       Date:  2009-04       Impact factor: 3.105

Review 10.  Phospholipase A2 biochemistry.

Authors:  John E Burke; Edward A Dennis
Journal:  Cardiovasc Drugs Ther       Date:  2008-10-18       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.